Patients with psoriatic arthritis ( P s A ) may not be optimally treated. The impact of the disease
extends beyond skin and joint symptoms, impairing quality of life. This indicates that the …

The aim of our study was to analyse the serum interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α),
interleukin-1β (IL-1β) and interferon-γ(IFN-γ) levels in patients with AS and their …

Objective To analyze whether inflammatory disease activity plays a substantial role in the
loss of bone mass observed in ankylosing spondylitis (AS) patients who have not yet …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …

Objective. The national registry of spondyloarthropathies (REGISPONSER) is launched to
classify patients with this group of diseases treated in Spanish rheumatology clinics. This …

Background Guselkumab, a human monoclonal antibody that binds to the p19 subunit of
interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic …

Objectives First, to investigate if switching biological disease-modifying antirheumatic drugs
(bDMARDs) after the failure to prior bDMARD is efficacious in patients with axial …

Objective Neovascularization, with an increased number of synovial vessels with a
characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). …

Objectives: To evaluate the prevalence and incidence of antimalarial myopathy in patients
with rheumatic diseases treated with antimalarial drugs. Methods: Over a three year period, all …

Objective To analyze the performance of psoriatic arthritis (PsA) screening tools, examine
their implementation in daily practice, and reach a consensus about the best screening tool for …